ClinicalTrials.gg
CompletedNCT02251769Updated Sep 29, 2014

Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

A Phase 1 interventional study of Tipranavir and Ritonavir in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-09-29.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

To determine the effects of single-dose and steady-state Tipranavir/Ritonavir (TPV/r) at 500 mg/200 mg bid on the steady-state pharmacokinetics of clarithromycin and to determine the effects of a standard high-fat test meal on the steady-state pharmacokinetics of tipranavir.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects between 18 and 60 years of age inclusive
  • A (BMI) between 18 and 29 kg/m2
  • Signed prior to trial participation
  • Ability to swallow multiple capsules without difficulty
  • Ability to ingest a standard high-fat test meal
  • Acceptable laboratory values that indicated adequate baseline organ function were required at the time of screening. Laboratory values were considered to be acceptable if severity was less than or equal to Grade 1, based on the AIDS Clinical Trials Group (ACTG) Grading Scale
  • Acceptable medical history, physical examination and 12-lead were required prior to entering the treatment phase of the study
  • Willingness to abstain from alcohol for 48 hours prior to study Day 0 and abstain from alcohol for the duration of the study. In addition, ingestion of red wine is not allowed within 5 days prior to Day 0 (Visit 2)
  • Willingness to abstain from grapefruit or grapefruit juice or products containing grapefruit juice starting 10 days prior to any administration of study drug up until the end of the study
  • Willingness to abstain from ingestion of Seville oranges, garlic supplements, St. John's Wort, or Milk Thistle, within 5 days of treatment and for the duration of the study
  • Willingness to abstain from methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.) within 48 hours of each pharmacokinetic sampling day and until after the last sample from each of the intensive sampling days was collected
  • Willingness to abstain from over the counter herbal medications for the duration of the study
  • Willingness to abstain from vigorous physical exercise during intensive pharmacokinetic days
  • Reasonable probability for completion of the study
  • Non-smokers for at least 3 months prior to Day 0

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are of and who:

    1. Have positive serum β-hCG at Visit 1, or on Day 0
    2. Are not using a barrier method for at least 3 months prior to Visit 2 (Day 0)
    3. Are not willing to use a reliable method of barrier contraception (such as diaphragm or condoms), during the trial and for 30 days after trial completion/termination
    4. Are breast-feeding
  • Use of any pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to study initiation and for the duration of the study
  • Use of hormone replacement therapy within 1 month prior to study initiation and for the duration of the study
  • Participation in another trial with an medicine within 60 days prior to Day 0 (Visit 2)
  • Use of any prohibited medication listed in the protocol within 30 days prior to Day 0 (Visit 2)
  • Administration of antibiotics within 10 days prior to Day 0 (Visit 2) or during the trial
  • History of acute illness within 60 days of trial initiation. Subjects are excluded for these disorders greater than 60 days if, in the opinion of the investigator, the subject does not qualify as a healthy volunteer
  • Serological evidence of (HBV) or (HCV)
  • Serological evidence of exposure to
  • Recent history of alcohol or substance abuse (within 6 months of study period)
  • Blood or plasma donations within 30 days prior to Day 0 (Visit 2) or during the trial
  • Subjects with a seated systolic blood pressure either \<100 mm Hg or >150 mm Hg
  • Subjects with a history of any illness or allergy that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering tipranavir (TPV), ritonavir (RTV) or clarithromycin (CLR) to the subject
  • Subjects who have taken, within 7 days prior to Day 0 (Visit 2), any over-the-counter or prescription drugs that, in the opinion of the investigator in consultation with the BI clinical monitor, might interfere with either the absorption, distribution or metabolism of the test substances
  • Known to TPV, RTV, sulfonamides, or CLR
  • Lactose intolerance or intolerance to high-fat foods
  • Allergies or intolerance to foods such as soybean, wheat, milk, eggs or gluten
  • Inability to adhere to requirements of the protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequential administration

    Drug: Tipranavir · Drug: Ritonavir · Drug: Clarithromycin · Other: High-Fat Test Meal

Interventions

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration time curve from 0-12 hours (AUC0-12h)

    Time frame: up to 12 hours

  2. Maximum plasma concentration (Cmax)

    Time frame: up to 12 hours

  3. Plasma trough concentration (Cp12h)

    Time frame: up to 12 hours

Secondary outcomes

  1. Oral clearance (CL/F)

    Time frame: up to 12 hours

  2. Volume of distribution (V)

    Time frame: up to 12 hours

  3. Apparent terminal half life (t1/2)

    Time frame: up to 12 hours

  4. Time of maximum concentration (Tmax)

    Time frame: up to 12 hours

  5. Mean Residency Time (MRT)

    Time frame: up to 12 hours

  6. Number of patients with adverse events

    Time frame: up to day 13

  7. Number of patients with clinically significant laboratory findings

    Time frame: up to day 13

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003 and a primary completion of Sep 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Sep 29, 2014
Start
Aug 2003
Primary completionActual
Sep 2003
Last update
Sep 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02251769
Responsible party
Sponsor
First posted
Sep 29, 2014
Start date
Aug 2003
Primary completion
Sep 2003
Last update
Sep 29, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Clarithromycin

Start the discussion